Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendationEric Legius, C. Oliver Hanemann, Ludwine Messiaen et al.|Genetics in Medicine|2021Cited by 766
Health Supervision for Children With Neurofibromatosis Type 1David T. Miller, Joan M. Stoler, Timothy A. Geleske et al.|PEDIATRICS|2019Cited by 231
Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a Neurofibromatosis Clinical Trials Consortium phase II studyBrian Weiss, Michael J. Fisher, Brigitte C. Widemann et al.|Neuro-Oncology|2014Cited by 147
A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1–associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium studyNicole J. Ullrich, Mark W. Kieran, Sanjay P. Prabhu et al.|Neuro-Oncology|2020Cited by 82
Discontinuation of Antiseizure Medications in Patients With Brain TumorsKatherine B. Peters, Maciej Mrgula, Jessica W. Templer et al.|Neurology|2024Cited by 15